Related Experiment Video
Updated: Apr 12, 2026
Oct4GiP Reporter Assay to Study Genes that Regulate Mouse Embryonic Stem Cell Maintenance and Self-renewal
Published on: May 30, 2012
The next new target in leukemia: The embryonic stem cell gene SALL4
Fei Wang1, Wenxiu Zhao2, Nikki Kong2
1Department of Pathology Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA ; Department of Clinical Laboratory; Peking Union Medical College Hospital; Peking Union Medical College and Chinese Academy of Medical Sciences; Beijing, China.
Abstract:
The embryonic stem (ES) cell gene SALL4 has recently been identified as a new target for cancer therapy, including leukemia. SALL4 is expressed in ES cells and during embryonic development, but is absent in most adult tissues. It is, however, aberrantly expressed in various solid tumors and hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Aberrant expression of SALL4 is frequently associated with a more aggressive cancer phenotype, which includes high-risk MDS and its progression to AML. SALL4 contributes to leukemogenesis through multiple pathways including the repression of PTEN and the activation of HOXA9 expression. Targeting the SALL4/PTEN pathway by blocking the protein-protein interaction of SALL4 and its associated epigenetic complex, nucleosome remodeling and deacetylase complex (NuRD), might be a novel approach to treating AML and holds great potential for the treatment of other SALL4-mediated oncogenic processes such as high-risk MDS and solid tumors.
Insights
The embryonic stem cell gene SALL4, normally absent in adults, drives leukemia by repressing PTEN. Targeting the SALL4/PTEN pathway offers a novel therapeutic strategy for acute myeloid leukemia and myelodysplastic syndromes.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- The embryonic stem (ES) cell gene SALL4 is crucial for development but typically absent in adult tissues.
- Aberrant SALL4 expression is linked to aggressive phenotypes in hematologic malignancies like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Purpose of the Study:
- To investigate the role of SALL4 in leukemogenesis.
- To explore the SALL4/PTEN pathway as a potential therapeutic target for AML and high-risk MDS.
Main Methods:
- Analysis of SALL4 expression patterns in cancer.
- Investigation of SALL4's molecular mechanisms, including PTEN repression and HOXA9 activation.
- Exploration of targeting the SALL4/NuRD complex interaction.
Main Results:
- SALL4 is aberrantly expressed in various cancers, correlating with aggressive disease, including high-risk MDS and AML.
- SALL4 contributes to leukemia development by repressing PTEN and activating HOXA9.
- Blocking SALL4's interaction with the NuRD complex shows potential for therapeutic intervention.
Conclusions:
- SALL4 is a key driver in leukemogenesis and a promising therapeutic target.
- Targeting the SALL4/PTEN pathway, specifically the SALL4/NuRD interaction, represents a novel strategy for treating AML and MDS.
- This approach may also benefit patients with other SALL4-mediated solid tumors.
More Related Videos
11:40Retroviral Infection of Murine Embryonic Stem Cell Derived Embryoid Body Cells for Analysis of Hematopoietic Differentiation
Published on: October 20, 2014
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
01:21Lineage Commitment
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:06Induced Pluripotent Stem Cells
Somatic...
01:29Somatic to iPS Cell Reprogramming
00:58Embryonic Stem Cells
00:57Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...